Avelumab and Radiation in Muscle-Invasive Bladder Cancer
A Phase 2 Study of Avelumab in Combination With Bladder-Directed Radiation in Cisplatin-Ineligible Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder
Sponsor: Dana-Farber Cancer Institute
Terminated
In agreement with the drug sponsor and the institution, the trial has been terminated due to slow accrual.
Other terminated trials from Dana-Farber Cancer Institute
Other Bladder Cancer trials with similar outcome
Listed as NCT03747419, this PHASE2 trial focuses on Bladder Cancer and Muscle Invasive Bladder Cancer and remains terminated or withdrawn. Sponsored by Dana-Farber Cancer Institute, it has been updated 16 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
16 versions recorded-
Nov 2025 — Present [monthly]
Terminated PHASE2
-
Jun 2025 — Nov 2025 [monthly]
Terminated PHASE2
-
Mar 2025 — Jun 2025 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Dec 2024 — Mar 2025 [monthly]
Recruiting PHASE2
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE2
▶ Show 11 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Jun 2023 — Jun 2024 [monthly]
Recruiting PHASE2
-
May 2022 — Jun 2023 [monthly]
Recruiting PHASE2
Status: Active Not Recruiting → Recruiting
-
Oct 2021 — May 2022 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE2
-
Mar 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE2
-
May 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Mar 2019 — May 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Dec 2018 — Mar 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Dana-Farber Cancer Institute
- EMD Serono
For direct contact, visit the study record on ClinicalTrials.gov .